Paul R. Edick, See Remarks at Xeris Biopharma Holdings, Inc. (XERS), bought 20,000 shares at $1.45 ($29K) on 2022-12-13, disclosed to the SEC on 2022-12-14.
Open-market purchase of $29k XERS by See Remarks. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| XERS | BUY | 2021-11-16 | $46K | — | Filing → |
| XERS | BUY | 2021-11-12 | $416K | — | Filing → |
| XERS | BUY | 2020-12-10 | $41K | — | Filing → |